webinar recording available - register to watch

Novel oncology trial designs with a personalized ctDNA assay

Discover the latest advantages of using a personalized, tumor-informed circulating tumor DNA (ctDNA) test to design oncology clinical trials in solid tumors. Learn how Signatera, a breakthrough technology, can be applied in early stage and late stage cancer trials, potentially enriching for patients most likely to respond to therapy, accelerating time to trial readout, or identifying early relapsers.

Topics will include:

  • Advantages of personalized, tumor-informed ctDNA assay for molecular residual disease detection
  • Signatera clinical data in early and late stage solid tumors
  • Growing site network to conduct trials with next-gen biotherapeutics
  • Applications of Signatera in clinical trial design to maximize trial success, and accelerate time to data readout.

Join this webinar to discover the applications of Signatera™, a novel assay that detects ctDNA with high sensitivity and specificity to monitor molecular residual disease (MRD), early recurrence, and treatment response across solid tumors in clinical trials.

watch now
watch the webinar

No cost to register, subject to confirmation

If you are experiencing problems with your registration, please try the Zoom registration page.

Angel Rodriguez

Angel Rodriguez

Medical Director, Oncology at Natera

Dr. Angel Augusto Rodriguez is a board certified medical oncologist who specializes in breast medical oncology and conducted clinical research with circulating tomorrow DNA. Before joining Natera, Dr. Rodriguez practices at Austin Cancer Centers and Houston Methodist Cancer Center where he was Director of the Clinical trials Office and the Triple Negative Breast Cancer Clinic. While at Houston Methodist he was the principal investigator of clinical trials and conducted clinical research with circulating tumor DNA.

Arsalan Arif
moderator

arsalan arif

Founder & CEO, Endpoints News

Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.